Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Gilead reported Q1 revenue of $7.0B (+4% YoY) and EPS of $1.61 (+54.8% YoY), supported by $5.0B (+10% YoY) in HIV sales and 79% gross margins. The company highlighted a 2026 launch slate including FDA accelerated approval for chronic hepatitis delta therapy (Bulevirtide, May 22), Priority Review for a BIC/LEN combo with an Aug. 27 PDUFA date, an Arcellx CAR-T (Dec PDUFA), and Trodelvy expansion into first-line mTNBC (FDA approval June 24). Shares are described as trading at ~15x forward earnings with a 2.39% dividend yield and a 3.7% dividend increase (11 straight years), which collectively improves the earnings outlook beyond HIV as acquisitions broaden the pipeline.

Analysis

GILD is transitioning from a mature cash-yield story into a self-funded pipeline call option, but the market is still pricing it like a low-growth pharma. The second-order setup is favorable: if long-acting HIV and oncology launches land, the company can redeploy operating cash into more BD without stressing the dividend, which should compress the "ex-growth" discount. That said, the equity won’t rerate on approval headlines alone; the stock needs evidence of gross-to-net stability and real prescription acceleration to justify a higher multiple.

The biggest near-term winner is GILD’s own equity beta to its August/December catalysts, while the losers are incumbent HIV and oncology franchises that rely on convenience or late-line inertia. Long-acting prevention is the more disruptive leg because it can shift share from chronic oral regimens over 12-24 months, not days, and that creates a broader read-through for GSK/ViiV-style HIV exposure. In oncology, the upside is more incremental: commercialization risk is high, so the market should discount launch curves until reimbursement and physician adoption are visible.

Contrarian view: the consensus is likely underestimating the durability of GILD’s cash engine but overestimating how quickly the new assets move the P&L. The acquisition-heavy strategy adds optionality, yet integration and launch execution are the gating variables. If the next two quarters show only modest sequential uplift or management trims 2026 launch assumptions, the rerating case fades quickly; conversely, a clean BIC/LEN decision plus early Yeztugo traction should support a multi-quarter grind higher.

Key Decisions for Investors

• Buy GILD on pullbacks into the Aug. 27 PDUFA, with a 3-6 month horizon; risk/reward favors a rerating toward mid-teens forward P/E if launch data and guidance firm up, but thesis is falsified if launch cadence slips or 2026 sales guidance is cut.
• Pair long GILD / short XBI over the next 1-3 months: GILD has identifiable commercial catalysts and balance-sheet support, while XBI remains exposed to binary clinical risk and multiple compression if rates stay sticky.
• If you want cleaner convexity, use Jan-2027 GILD call spreads rather than outright calls; the market is unlikely to fully price 2026 launch economics today, but downside is limited if adoption disappoints.
• Watch GSK as the indirect loser in long-acting HIV prevention; if GILD’s prevention uptake accelerates into year-end, consider a relative-value short GSK / long GILD basket.
• Do not chase ACLX on the headline unless merger terms leave a spread open; the takeover already caps upside, so the better expression is GILD if you want exposure to the acquired pipeline rather than the target equity.